#capitello281 search results
#KarimFizazi with primary analysis of #CAPITELLO281, capivasertib w ADT in metastatic hormone sensitive #prostatecancer improved rPFS for PTEN deficient disease. 👏👏 >6000 patients screened (!!) Concurrent pub @Annals_Oncology @myESMO @OncoAlert #ESMO25 #ESMOAmbassadors
#CAPItello281 (phase II) of #capivasertib + abi showed #rPFS #benefit (33.2 v 25.7m, HR 0.81, CI 0.66-0.98) v. abi in #PTEN deficient, de novo #mHSPC, representing potential first-in-class target for this poor prognosis population and stress imp of early NGS testing #ESMO25
5 GU studies that we focused on during our conference highlight discussion with @bergsa83 from #ESMO25: ✅ #PSMAddition by @DrScottTagawa ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905/EV303 ✅ #IMvigor011 by @tompowles1 #gusm #OncTwitter #MedTwitter @OncUpdates
GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO
4. #CAPItello281: PhIII, Abi + ADT +/- Capivasertib (approved for PIK3/AKT/PTEN in breast cancer - Nov 2023) in PTEN deficient de-novo mHSPC: - Median rPFS 33.2 vs 25.7mos (HR: 0.81) - OS immature - AEs: Rash, Hyperglycemia, and diarrhea 6/11
Primary result of Ph3 CAPItello-281 in PTEN-deficient mHSPC #ProstateCancer by @fizazi_karim #ESMO25 👉adding capivasertib + abiraterone to ADT improved rPFS vs abi+ADT (33.2 vs 25.7 mo; HR 0.81, p= 0.034). OS immature; ↑rash & hyperglycemia with Capi @OncoAlert @urotoday
GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO
5 GU studies that we focused on during our conference highlight discussion with @bergsa83 from #ESMO25: ✅ #PSMAddition by @DrScottTagawa ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905/EV303 ✅ #IMvigor011 by @tompowles1 #gusm #OncTwitter #MedTwitter @OncUpdates
GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO
GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO
4. #CAPItello281: PhIII, Abi + ADT +/- Capivasertib (approved for PIK3/AKT/PTEN in breast cancer - Nov 2023) in PTEN deficient de-novo mHSPC: - Median rPFS 33.2 vs 25.7mos (HR: 0.81) - OS immature - AEs: Rash, Hyperglycemia, and diarrhea 6/11
Primary result of Ph3 CAPItello-281 in PTEN-deficient mHSPC #ProstateCancer by @fizazi_karim #ESMO25 👉adding capivasertib + abiraterone to ADT improved rPFS vs abi+ADT (33.2 vs 25.7 mo; HR 0.81, p= 0.034). OS immature; ↑rash & hyperglycemia with Capi @OncoAlert @urotoday
#KarimFizazi with primary analysis of #CAPITELLO281, capivasertib w ADT in metastatic hormone sensitive #prostatecancer improved rPFS for PTEN deficient disease. 👏👏 >6000 patients screened (!!) Concurrent pub @Annals_Oncology @myESMO @OncoAlert #ESMO25 #ESMOAmbassadors
#CAPItello281 (phase II) of #capivasertib + abi showed #rPFS #benefit (33.2 v 25.7m, HR 0.81, CI 0.66-0.98) v. abi in #PTEN deficient, de novo #mHSPC, representing potential first-in-class target for this poor prognosis population and stress imp of early NGS testing #ESMO25
#KarimFizazi with primary analysis of #CAPITELLO281, capivasertib w ADT in metastatic hormone sensitive #prostatecancer improved rPFS for PTEN deficient disease. 👏👏 >6000 patients screened (!!) Concurrent pub @Annals_Oncology @myESMO @OncoAlert #ESMO25 #ESMOAmbassadors
5 GU studies that we focused on during our conference highlight discussion with @bergsa83 from #ESMO25: ✅ #PSMAddition by @DrScottTagawa ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905/EV303 ✅ #IMvigor011 by @tompowles1 #gusm #OncTwitter #MedTwitter @OncUpdates
GU Malignancy Highlights from #ESMO25 w/ @bergsa83! 5 key studies: ✅ #PSMAddition ✅ #CAPItello281 ✅ #POTOMAC ✅ #Keynote905 ✅ #IMvigor011 Full Discussion: - oncbrothers.com/esmo-gu-2025 - Also on the “Oncology Brothers” podcast #OncTwitter #gusm @OncUpdates @myESMO
#CAPItello281 (phase II) of #capivasertib + abi showed #rPFS #benefit (33.2 v 25.7m, HR 0.81, CI 0.66-0.98) v. abi in #PTEN deficient, de novo #mHSPC, representing potential first-in-class target for this poor prognosis population and stress imp of early NGS testing #ESMO25
4. #CAPItello281: PhIII, Abi + ADT +/- Capivasertib (approved for PIK3/AKT/PTEN in breast cancer - Nov 2023) in PTEN deficient de-novo mHSPC: - Median rPFS 33.2 vs 25.7mos (HR: 0.81) - OS immature - AEs: Rash, Hyperglycemia, and diarrhea 6/11
Primary result of Ph3 CAPItello-281 in PTEN-deficient mHSPC #ProstateCancer by @fizazi_karim #ESMO25 👉adding capivasertib + abiraterone to ADT improved rPFS vs abi+ADT (33.2 vs 25.7 mo; HR 0.81, p= 0.034). OS immature; ↑rash & hyperglycemia with Capi @OncoAlert @urotoday
Something went wrong.
Something went wrong.
United States Trends
- 1. Good Thursday 26.8K posts
- 2. #GrabFoodMegaSalexหลิงออม 401K posts
- 3. Cynthia 55.3K posts
- 4. #WorldKindnessDay 8,693 posts
- 5. Larry Brooks N/A
- 6. Rejoice in the Lord 2,288 posts
- 7. SUSDT N/A
- 8. RIP Brooksie N/A
- 9. #SwiftDay N/A
- 10. #thursdaymotivation 1,893 posts
- 11. PancakeSwap BNB Chain N/A
- 12. RIP Larry N/A
- 13. Happy Friday Eve N/A
- 14. #thursdayvibes 2,566 posts
- 15. Michael Burry 7,164 posts
- 16. Jesse Jackson 1,372 posts
- 17. Namjoon 102K posts
- 18. Eddie Guerrero 3,732 posts
- 19. Jokic 31.3K posts
- 20. Horizon 28.7K posts